Advertisement
Screener

Moleculin Biotech, Inc. (MBRX) Retained Earnings

2.8 / 5 stars · 68/120 Roast Me

Moleculin Biotech, Inc. Retained Earnings

Moleculin Biotech, Inc. (MBRX) had Retained Earnings of -$226.48 million as of 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent

us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-13

  • 2026-06-30: Retained Earnings (Accumulated Deficit) -$226.48M.
  • 2026-03-31: Retained Earnings (Accumulated Deficit) -$218.85M.
  • 2025-12-31: Retained Earnings (Accumulated Deficit) -$206.00M.
  • 2025-09-30: Retained Earnings (Accumulated Deficit) -$221.56M.
Period endRetained Earnings (Accumulated Deficit)Retained Earnings (Accumulated Deficit) as first filed
2026-06-30-$226.48M
10-Q · filed 2026-08-13
2026-03-31-$218.85M
10-Q · filed 2026-05-14
2025-12-31-$206.00M
10-Q · filed 2026-08-13
2025-09-30-$221.56M
10-Q · filed 2025-11-13
2025-06-30-$196.16M
10-Q · filed 2025-11-13
-$167.44M
10-Q · filed 2025-08-12
2025-03-31-$178.35M
10-Q · filed 2025-11-13
-$159.80M
10-Q · filed 2025-05-13
2024-12-31-$172.44M
10-K · filed 2026-03-18
-$153.37M
10-K · filed 2025-03-21
2024-09-30-$151.49M
10-Q · filed 2024-11-08
2024-06-30-$140.89M
10-Q · filed 2024-08-13
2024-03-31-$136.57M
10-Q · filed 2024-05-10
2024-01-01-$146.40M
10-Q · filed 2026-08-13
2023-12-31-$131.60M
10-K · filed 2025-03-21
2023-09-30-$121.33M
10-Q · filed 2023-11-13
2023-06-30-$115.73M
10-Q · filed 2023-08-10
2023-03-31-$109.75M
10-Q · filed 2023-05-10
2022-12-31-$101.83M
10-K · filed 2024-03-22
2022-09-30-$95.06M
10-Q · filed 2022-11-10
2022-06-30-$86.45M
10-Q · filed 2022-08-12
2022-03-31-$79.68M
10-Q · filed 2022-05-11
2021-12-31-$72.81M
10-K · filed 2023-03-22
2021-09-30-$69.98M
10-Q · filed 2021-11-10
2021-06-30-$65.61M
10-Q · filed 2021-08-11
2021-03-31-$61.36M
10-Q · filed 2021-05-12
2020-12-31-$56.92M
10-K · filed 2022-03-24
2020-09-30-$54.28M
10-Q · filed 2020-11-12
2020-06-30-$50.88M
10-Q · filed 2020-08-12
2020-03-31-$40.77M
10-Q · filed 2020-05-11
2019-12-31-$39.56M
10-K · filed 2021-03-24
2019-09-30-$35.76M
10-Q · filed 2019-11-12
2019-06-30-$31.62M
10-Q · filed 2019-08-16
2019-03-31-$30.40M
10-Q · filed 2019-05-13
2018-12-31-$26.36M
10-K · filed 2020-03-19
2018-09-30-$23.57M
10-Q · filed 2018-11-13
2018-06-30-$21.53M
10-Q · filed 2018-08-10
2018-03-31-$16.41M
10-Q · filed 2018-05-14
2017-12-31-$14.48M
10-K · filed 2019-02-21
2017-09-30-$11.29M
10-Q · filed 2017-11-13
2017-06-30-$8.43M
10-Q · filed 2017-08-11
2017-03-31-$5.00M
10-Q · filed 2017-05-12
2016-12-31-$4.67M
10-K · filed 2018-03-28
-$4.67M
10-K · filed 2017-04-03
2016-09-30-$3.25M
10-Q · filed 2016-11-21
2016-06-30-$1.82M
10-Q · filed 2016-11-21
-$2.08M
10-Q · filed 2016-08-15
2016-03-31-$1.08M
10-Q · filed 2016-06-16
2015-12-31-$748.36K
10-K · filed 2017-04-03

Similar stocks

Stock NameCountryMarket CapPE Ratio
MetaVia Inc. (MTVA)United States$0.011B-0.65
KALA BIO, Inc. (KALA)United States$0.011B-3.33
Theriva Biologics, Inc. (TOVX)United States$0.011B
Dare Bioscience, Inc. (DARE)United States$0.011B
Azitra, Inc. (AZTR)United States$0.010B-0.81
Medicus Pharma Ltd. (MDCX)$0.010B
KIORA PHARMACEUTICALS INC (KPRX)United States$0.012B
Scienture Holdings, Inc. (SCNX)United States$0.012B-0.38
Aprea Therapeutics, Inc. (APRE)United States$0.010B-0.78
Phio Pharmaceuticals Corp. (PHIO)United States$0.012B-0.92